Fumaric acid esters

DRUG5 trials

Sponsors

Medical University of Vienna, University Hospital Muenster, Eli Lilly and Company, Janssen-Cilag G.m.b.H, LEO Pharma

Conditions

Lupus Erythematosus, CutaneousPlaque PsoriasisPsoriasisPsoriasis Vulgaris

Phase 2

Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus

CompletedNCT01352988

University Hospital MuensterLupus Erythematosus, Cutaneous

Start: 2011-07-31End: 2014-02-28Updated: 2014-02-28

Phase 3

Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis

CompletedNCT01321164

Medical University of ViennaPlaque Psoriasis

Start: 2011-04-30End: 2014-04-30Updated: 2014-05-12

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment

CompletedNCT02634801

Eli Lilly and CompanyPlaque Psoriasis

Start: 2016-01-20End: 2017-11-14Updated: 2019-10-09

A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

CompletedNCT02951533

Janssen-Cilag G.m.b.HPsoriasis

Start: 2016-12-12End: 2019-02-06Updated: 2020-02-28

Phase 4

A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

CompletedNCT03331835

LEO PharmaPsoriasis Vulgaris

Start: 2017-11-03End: 2019-03-21Updated: 2025-03-13

Related Papers

A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.

2019-11-1931 citations

Prevalence of genital psoriasis in patients with psoriasis.

2018-03-2849 citations